11 Apr 2018securities registration● Neutral
Arcadia Biosciences, Inc. filed notice of an exempt private placement.
Announcements, explained
Each one in plain English, with the numbers worked through for a shareholder.
30 Mar 2018securities registration● Neutral
Arcadia Biosciences, Inc. registered a securities offering with the SEC using its shelf eligibility.
23 Mar 2018capital raising announcement▼ BadMajor
Arcadia raised capital in a structured private placement -- 300,752 shares plus warrants initially priced at $45.75 -- with unusual downward-resetting pricing mechanics that could cut the purchase/exercise price to as low as $8.322 depending on later trading prices, a sign of a weak bargaining position typical of a company under Nasdaq compliance pressure.
9 Mar 2018substantial holder notice● Neutral
Moral Compass Corporation, Terri Bishop, Peter Sperling, Darby Shupp, John G. Sperling reported a Arcadia Biosciences, Inc. shareholding of 1,125,769 shares (52.80% of votes) in a periodic institutional filing.
21 Nov 2017director interest notice● Neutral
Arcadia Biosciences, Inc. VP Product Development Zhongjin Lu sold 5,950 shares at $0.23.
9 Nov 2017quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported a quarterly net loss of $4.5 million for the period ended 2017-09-30.
9 Nov 2017quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported a quarterly net loss of $4.5 million for the period ended 2017-09-30.
11 Aug 2017director interest notice● Neutral
Amy Yoder became a Arcadia Biosciences, Inc. director and company insider (initial ownership filing).
10 Aug 2017quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported a quarterly net loss of $4.0 million for the period ended 2017-06-30.
9 Aug 2017director interest notice● Neutral
Arcadia Biosciences, Inc. director Amy Yoder received a stock option grant for 202,447 shares.
9 Aug 2017director interest notice● Neutral
Amy Yoder became a Arcadia Biosciences, Inc. director and company insider (initial ownership filing).
16 June 2017director interest notice● Neutral
George Frederick John Gosbee became a Arcadia Biosciences, Inc. director and company insider (initial ownership filing).
12 June 2017director interest notice● Neutral
Arcadia Biosciences, Inc. director Eric J. Rey bought 5,000 shares on the open market at $0.75.
9 June 2017director interest notice● Neutral
Arcadia Biosciences, Inc. director Gregory D Waller received a stock option grant for 119,377 shares.
9 June 2017director interest notice● Neutral
Arcadia Biosciences, Inc. VP Product Development Zhongjin Lu received a stock option grant for 50,000 shares.
9 June 2017director interest notice● Neutral
Eric J. Rey became a Arcadia Biosciences, Inc. director and company insider (initial ownership filing).
9 June 2017director interest notice● Neutral
Arcadia Biosciences, Inc. director Uday Garg received a stock option grant for 60,350 shares.
9 June 2017director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Executive Officer Rajendra D. Ketkar received a stock option grant for 325,000 shares.
9 June 2017director interest notice● Neutral
Gregory D Waller became a Arcadia Biosciences, Inc. director and company insider (initial ownership filing).
9 June 2017director interest notice● Neutral
Arcadia Biosciences, Inc. director Eric J. Rey received a stock option grant for 119,377 shares.
9 June 2017director interest notice● Neutral
Arcadia Biosciences, Inc. Chief Financial Officer Matthew T Plavan received a stock option grant for 225,000 shares.
9 June 2017director interest notice● Neutral
Arcadia Biosciences, Inc. director Kevin Comcowich received a stock option grant for 60,350 shares.
9 June 2017director interest notice● Neutral
Arcadia Biosciences, Inc. director George Frederick John Gosbee received a stock option grant for 80,466 shares.
30 May 2017listing compliance notice▼ BadMajor
A second, simultaneous Nasdaq deficiency: the market value of Arcadia's publicly held shares fell below the $5 million minimum, stacked on top of the still-unresolved minimum bid price problem from February.
10 May 2017quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported a quarterly net loss of $4.2 million for the period ended 2017-03-31.
10 May 2017quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported a quarterly net loss of $4.2 million for the period ended 2017-03-31.
10 Mar 2017substantial holder notice● Neutral
Moral Compass Corporation, Terri Bishop, Peter Sperling, Darby Shupp, John G. Sperling reported a Arcadia Biosciences, Inc. shareholding of 22,515,364 shares (50.60% of votes) in a periodic institutional filing.
17 Feb 2017listing compliance notice▼ BadMajor
Arcadia's stock fell out of compliance with Nasdaq's $1.00 minimum bid price requirement -- the first of what would become a recurring Nasdaq compliance problem for the company over the following decade.
10 Nov 2016quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported a quarterly net loss of $4.2 million for the period ended 2016-09-30.
10 Nov 2016quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported a quarterly net loss of $4.2 million for the period ended 2016-09-30.